21 CFR Part 211 details the current good manufacture practice for finished pharmaceuticals. It covers requirements ... the component as labeled prior to release for use in drug product manufacturing.

Gland Pharma Ltd. received the establishment inspection report from US FDA, confirming that the good manufacturing practices ...

Gland Pharma Ltd shares gained almost 3% on Thursday after the company announced receiving a Good Manufacturing Practice (GMP ...

India extended the deadline for small- and medium-sized pharmaceutical companies to comply with revised GMP compliance under ...

Pharmaceutical manufacturing encompasses ... records to ensure the integrity of their data, as well as Good Manufacturing Practices (GMP), which emphasizes the need to comply with strict quality ...

These companies now have until December 31, 2025, to upgrade their facilities and meet the enhanced standards. The extension ...

To support compliance, the government revised Schedule M of the Drugs and Cosmetics Rules, 1945, in 2023, outlining phased ...

Small and medium-sized pharmaceutical companies are preparing to comply with the provisions of the revised Schedule M, which ...

Gland Pharma announced that it has received an establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Pashamylaram facility at Hyderabad.

Innovation, institutions, integration, and infrastructure are the four key factors that will drive this sector ...

The new Schedule M will be implemented from 1 January, 2026, to help MSMEs adjust to updated manufacturing standards.

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce the ...